Skip To Main Content
Anna Dolnik on Muck Rack

Anna Dolnik

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Anna Dolnik’s profile

Articles by Anna Dolnik

Single-cell multiomics analysis reveals dynamic clonal evolution and targetable phenotypes in acute myeloid leukemia with complex karyotype - Nature Genetics

|
By Aino-Maija Leppä, Karen Grimes, Hyobin Jeong, Patrick Stelmach, Carsten Müller-Tidow, Anna Dolnik, Lars Bullinger, Krzysztof Mrózek, Ann-Kathrin Eisfeld, Ashley Sanders, Jan Korbel
| Nature Verified
Abstract Chromosomal instability is a major driver of intratumoral heterogeneity (ITH), promoting tumor progression. In the present study, we combined structural variant discovery and nucleosome occupancy profiling with transcriptomic and immunophenotypic changes in single cells to study ITH in complex karyotype acute myeloid leukemia (CK-AML).
Open in Who Shared Issue with article?

Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation

|
By Anna Dolnik, Sibylle Cocciardi, Silke Kapp-Schwoerer, Frank G. Rücker
| Nature Verified
Abstract Mutations in the nucleophosmin 1 (NPM1) gene are considered founder mutations in the pathogenesis of acute myeloid leukemia (AML). To characterize the genetic composition of NPM1 mutated (NPM1mut) AML, we assess mutation status of five recurrently mutated oncogenes in 129 paired NPM1mut samples obtained at diagnosis and relapse. We find a substantial shift in the genetic pattern from diagnosis to relapse including NPM1mut loss (n = 11).
Open in Who Shared Issue with article?

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care

|
By Hartmut Döhner, Lin Tang, John F. Seymour, Anna Dolnik
| Nature Verified
Prognosis is dismal for older patients with AML and Adverse-risk cytogenetics, including those with complex or monosomal karyotypes. Approximately one-third of patients in AZA-AML-001 had an Adverse karyotype; median OS among azacitidine-treated patients was almost double that of patients treated with CCR. Similarly, azacitidine-treated patients with monosomal or complex karyotypes had 35 and 36% reduced risks of death, respectively, compared with similar patients who received CCR.
Open in Who Shared Issue with article?
Show More